Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O00418
UPID:
EF2K_HUMAN
Alternative names:
Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase
Alternative UPACC:
O00418; Q8N588
Background:
Eukaryotic elongation factor 2 kinase, also known as Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase, plays a pivotal role in protein synthesis. It regulates the rate of peptide chain elongation by phosphorylating the elongation factor EEF2, rendering it inactive and thus reducing protein synthesis. This process is controlled by activation through various upstream kinases, including AMPK or TRPM7.
Therapeutic significance:
Understanding the role of Eukaryotic elongation factor 2 kinase could open doors to potential therapeutic strategies.